First Brands Group debt targeted by Apollo Global Management - report
HOUSTON - FibroBiologics, Inc. (NASDAQ:FBLG), a clinical-stage biotechnology company with a market capitalization of $22.55 million, announced advancements in its Bone Marrow Organoid platform that may offer new treatment options for hematopoietic cancers and age-related immune decline, according to a company press release.
Pre-IND animal trials showed that transplantation of the company’s proprietary Bone Marrow Organoids into a xenografted melanoma mouse model significantly reduced tumor size. The technology also enables efficient ex vivo gene editing for targeted therapeutic interventions before transplantation.
The organoids can be cryopreserved, potentially offering a scalable treatment option for bone marrow transplantation. The company indicated these developments support its pre-IND enabling development, moving toward clinical translation of the technology.
"Our organoid platform has the potential to do much more than target cancer," said Hamid Khoja, Chief Scientific Officer of FibroBiologics. "We see potential opportunities to help regenerate one or more desired immune cell type, counter age-related immune system decline, and restore immune function in patients with a compromised immune system."
Pete O’Heeron, Founder and Chief Executive Officer, described the advancements as "an important milestone" in addressing cancer and immune-related diseases.
FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials. The company holds 270+ issued and pending patents across various clinical pathways.
The company’s statements about potential applications and benefits of its technology represent forward-looking statements that involve risks and uncertainties, including the unpredictable relationship between research and clinical results.
In other recent news, FibroBiologics, Inc. announced that it has filed a patent application with the United States Patent and Trademark Office. This patent application pertains to methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. The techniques detailed in the application aim to produce larger quantities of stable and scalable multipotent cells directly from donor-derived fibroblasts. According to FibroBiologics, these multipotent fibroblasts have an enhanced ability to form 3D spheroid structures. This development could potentially expand their use across various therapeutic and drug development areas. The company’s move to secure a patent underscores its commitment to advancing cell-based therapies. These recent developments highlight FibroBiologics’ ongoing efforts to innovate in the field of regenerative medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.